In a latest update, Hyderabad-based pharmaceutical company Hetero Drugs has reached an agreement with the Russian Direct Investment Fund (RDIF) to make over 100 million doses per year of the RDIF's Sputnik-V vaccine against COVID-19 in India According to the official statement by RDIF, the companies will begin the production of the vaccine at the beginning of 2021.
The agreement has been reached by Hetero Drugs through its biologics conglomerate 'Hetero Biopharma'. The two parties intend to initiate the production of Sputnik V at the start of 2021.
Hetero Labs Limited, Director of International Marketing, B Murali Krishna Reddy, said, “We are pleased to collaborate with RDIF as a manufacturing partner for Sputnik V vaccine. While we look forward to the clinical trial results in India, we believe that manufacturing the product locally is crucial to enable swift access to patients. This collaboration is another step towards our commitment in the battle against COVID-19,”
Earlier in September 2020, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials and distribution of Sputnik V vaccine in India as part of which RDIF shall supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval.